4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

8-K/A - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

SC 13D - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled 27% Objective Response Rate (ORR) 33% Clinical Benefit Rate (CBR) with a median Progression Free Survival (PFS) of 57 weeks Chemotherapy-free immunomodulatory regimen well-tolerated with no documented serious immune-related adverse events CRANFORD, N.J., Nov. 11, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR) and Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), today announced promising preliminary results from an ongoing investigator-initiated Ph

CEO Leonard Mazur to present on Tuesday, September 10, 2024, at 9:00 am ET CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), today announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C. Wainwright & Co. 26th Annual Global Investment Conference taking place September 9–11, 2024, in New York City. H.C. Wainwright Conference Details:                Presentation: 9:00 am ET on Tuesday, September 10, 2024* Location: Lotte New York Palace Hotel, New York City Registration: Available on the conference website. 1x1 meetings: Requests available upon registration or by cont

CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR) and Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), today announced that LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). LYMPHIR is included based on an NCCN Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with Cutaneous T-cell Lymphoma (CTCL).    LYMPHIR (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of